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Intramembranous ossiﬁcationRs1–3 cause craniosynostosis (CS), the premature fusion of cranial bones, in man
and mouse. The mechanisms by which such mutations lead to CS have been variously ascribed to increased
osteoblast proliferation, differentiation, and apoptosis, but it is not always clear how these disturbances
relate to the process of suture fusion. We have reassessed coronal suture fusion in an Apert Fgfr2 (S252W)
mouse model. We ﬁnd that the critical event of CS is the early loss of basal sutural mesenchyme as the
osteogenic fronts, expressing activated Fgfr2, unite to form a contiguous skeletogenic membrane. A mild
increase in osteoprogenitor proliferation precedes but does not accompany this event, and apoptosis is
insigniﬁcant. On the other hand, the more apical coronal suture initially forms appropriately but then
undergoes fusion, albeit at a slower rate, accompanied by a signiﬁcant decrease in osteoprogenitor
proliferation, and increased osteoblast maturation. Apoptosis now accompanies fusion, but is restricted to
bone fronts in contact with one another. We correlated these in vivo observations with the intrinsic effects of
the activated Fgfr2 S252W mutation in primary osteoblasts in culture, which show an increased capacity for
both proliferation and differentiation. Our studies suggest that the major determinant of Fgfr2-induced
craniosynostosis is the failure to respond to signals that would halt the recruitment or the advancement of
osteoprogenitor cells at the sites where sutures should normally form.
© 2009 Elsevier Inc. All rights reserved.Introduction
Activating mutations in FGFRs1–3 are the basis of many human
bone morphogenetic disorders, as they affect the proliferation and
differentiation of both chondrocytes and osteoblasts, the two major
cell types involved in skeletal development. The shortened long bones
and chondrodysplasias observed in humans and mice with activating
FGFR3 mutations ﬁnd a relatively simple explanation in the growth
inhibitory and pro-apoptotic effects of FGF signaling in chondrocytes,
where FGFR3 is highly expressed (Marie et al., 2005; Ornitz, 2005;
Ornitz and Marie, 2002). However, the craniosynostosis syndromes
produced by misregulated FGF signaling in osteoblasts currently defy
a simple molecular explanation.
Craniosynostosis (CS) is the premature fusion of the ﬂat bones of
the skull. These bones form by intramembranous ossiﬁcation, in
which osteoblasts differentiate directly from osteogenic mesenchymal
cells. Fibrous joints (sutures) between these bones act as growth sites
to allow for skull growth to coordinate with and accommodate the
growing brain, and the premature fusion of one or more of thesesilico).
Regenerative Biology, Mt. Sinai
ce, New York, NY 10029, USA.
l rights reserved.sutures in CS adversely affects subsequent cranial and brain develop-
ment (Opperman, 2000). The most commonly identiﬁed genetic
lesions in syndromic CS are activating mutations in FGFRs1–3 and
inactivating mutations of the transcription factor TWIST (Morriss-Kay
and Wilkie, 2005). Apert syndrome is largely caused by activating
mutations of Serine252 or Proline253 in FGFR2 (Wilkie et al., 1995).
The affected residues lie in the linker region connecting the
extracellular immunoglobulin-like domains II and III, affect both
mesenchymal and epithelial splice forms of the receptor, and allow
each to respond to a wider range of FGF ligands, increasing signaling
(Yu et al., 2000). Premature fusion of the coronal suture is the primary
skull defect of Apert syndrome (Cohen and Kreiborg, 1996).
The Serine252Tryptophan (S252W) mutation in mouse has been
generated independently in two different laboratories (Chen et al.,
2003; Wang et al., 2005). In the mouse, the coronal suture normally
remains patent throughout life. The ﬁrst Apert mouse model (Chen
et al., 2003) demonstrated coronal suture fusion ﬁrst signaled by an
increased overlap of the frontal and parietal bones prenatally,
followed by their progressive fusion from about postnatal (P) day 4.
No differences in cell proliferation or differentiation of coronal suture
osteoblasts was noted betweenwild-type (WT) and mutant mice, but
an increase in the level of apoptosis in the mutant suture was
proposed as the cause for suture fusion. In the second Apert mouse
model midline sutures were affected differentially, while coronal and
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(Wang et al., 2005).
The development of effective therapies for craniosynostosis
requires an understanding of the process of suture fusion. Premature
fusion of the cranial sutures in humans andmicewith activating FGFR2
mutations has been varyingly ascribed to increased osteoblast
proliferation, differentiation, or apoptosis (Chen et al., 2003; Eswar-
akumar et al., 2004; Marie et al., 2002). In culture, sustained FGF
signaling stimulates osteoblast proliferation and inhibits their differ-
entiation, while also increasing apoptosis when cells are exposed to
differentiating conditions, but it is still not clear how theseﬁndings can
be reconciled with the observations made in vivo (Mansukhani et al.,
2000; Tang et al., 1996).
To identify the critical steps in osteoblast development that
determine the cranial malformations caused by an activated Fgfr2,
we have re-examined the mouse model of Apert syndrome described
by Chen et al. (2003), and tried to correlate the observations made in
vivo in this animal model with the study of the properties of
osteoblasts derived from the calvaria of the same mutant mice in
culture. The results presented in this report show that suture fusion is
a very early embryonic event in this Apert model, which is
accompanied by an initial increase in cell proliferation followed by
accelerated differentiation, as osteoblasts replace sutural mesench-
yme. In mutant sutures, mature osteoblasts invade the sites where
sutures should be formed and obliterate them. In culture, mutant
osteoblasts also exhibit increased proliferation and ability to differ-
entiate, and a variable downregulation of Fgfr2 expression. Our results
suggest that themajor determinant of craniosynostosis induced by the
Apert Fgfr2 mutation is the failure of the mutant suture mesenchyme
to respond to the signals that would normally prevent the induction of
the osteoblastic fate at the suture sites.
Methods
Mice
Micewere initially bred from a founding pair (male Fgfr2NeoS252W/+;
female EIIa-Cre). They were also outbred to a Swiss-Webster back-
ground. Mice were genotyped by PCR of genomic DNA prepared
from tail-tips or cultured cells for Fgfr2, Neo, and Cre. The primers
for Fgfr2 were as described (Chen et al., 2003). The sizes of the WT
and Cre-excised mutant products were 393 bp and 457 bp, respec-
tively, were conﬁrmed by sequencing, and agree with published
genomic sequence. These primers did not amplify the Neo-containing
mutant allele under the PCR conditions used. The Neo primers were
5′-AGGATCTCCTGTCATCTCACCTTGCTCCTG-3′ and 5′-AAGAACTCGT-
CAAGAAGGCGATAGAAGGCG-3′ (492 bp). The Cre primers were 5′-
CCTGGAAAATGCTTCTGTCCGTTTGCC-3′ and 5′-GAGTTGATAGCTGGCT-
GGTGGCAGATG-3′ (640 bp). Cre PCR was performed with 10% DMSO.
Histology and RNA in situ hybridization (ISH)
Embryos were ﬁxed in 4% paraformaldehyde (PFA) in PBS at 4 °C
overnight, washed in PBS, equilibrated with 30% sucrose/PBS, then
embedded in Tissue-Tek OTC Compound (Sakura, Japan). All PBS
solutions were pre-treated with DEPC. Frozen sections of 10 μm
thickness were cut on a Microm Cryostat and transferred to Super-
frost/Plus microscope slides (Fisher Scientiﬁc, USA).
Alkaline phosphatase (Alp) histochemistry was performed as
described previously (Miao and Scutt, 2002), except that frozen
sections were ﬁrst dried at 37 °C for 30 min, rehydrated in PBS for
5 min, and incubated with 0.1 M Tris-maleate buffer, before detection
with Fast Red TR/napthol AS-MX phosphate. For whole-mount
detection of Alp at E12.5, ﬁxed heads were stained with BM Purple
AP Substrate (Roche). RNA in situ hybridization (ISH) was performed
essentially as described (Xu and Wilkinson, 1999), except that oldersections were treated with up to 75 μg/ml of Proteinase K for 10 min;
RNase treatment was generally omitted. RNA riboprobes were
prepared with DIG RNA Labeling Mix as described by the manufac-
turer (Roche). Fgfr1 and Fgfr2 clones were from G. Morriss-Kay (Iseki
et al., 1999); rat Osteopontin (Spp1) is described (Oldberg et al., 1986);
Osteocalcin (Ocn) and Twist1were from C. Loomis (Deckelbaum et al.,
2006; Rice et al., 2000). A 1 kb full-length Noggin clone was sub-
cloned from an Invitrogen BMAP EST clone.
Cell proliferation
For in vivo BrdU incorporation, pregnant mice were injected with
BrdU (100 μg/g body weight) and sacriﬁced 30 min later. Embryos
were genotyped and processed as described for ISH. After drying and
staining for Alp activity, slideswere immunostained for BrdU using the
Amersham anti-BrdU kit and either Vector MOM staining kit with VIP
visualization of HRP activity, or immunoﬂuorescent detection with
anti-mouse Alexa488 conjugates. Sections were then stained with
Hoechst 33258 nuclear dye, washed, and mounted with Dapko
immunoﬂuorescence medium. Total (Hoechst-stained) nuclei and
Alp stain were visualized under the appropriate ﬂuorescence, and
BrdU-positive nuclei with white light or ﬂuorescence. Photos of each
component of each section were combined in Photoshop for nuclei
counting. Four to seven alternate sections, separated by 60–100 μm,
were used for each comparison, choosing sections from the same level
within the coronal suture, as judged by overall orientation of the
sections, betweenWT and Fgfr2S252W/+ littermates, above the level of
any fusion in Fgfr2S252W/+ sutures. Nuclei were counted if they were
within or immediately adjacent to the Alp signal of the OFs, within a
130 μm distance at E12.5–E13.5, when the OFs lack osteoid and
proliferating cells arewidespreadwithin the bone anlagen, andwithin
approximately 70 μmdistance at E14.5–E16.5, when proliferating cells
become more restricted to the leading edges of the OFs. Counts were
made for both individual – i.e. frontal and parietal – OFs, and for
intervening sutural mesenchyme, when possible. For cultured cells,
cells plated in 8-well chamber slides (LabTek, Nalgene-Nunc Interna-
tional)were labeledwith BrdU (4 μg/ml) for 4 h. The treated cellswere
ﬁxed in 3.7% PFA, and permeabilized with 0.5% Triton in PBS for 5 min,
followed by 1.5 M HCl for 15 min. After washing, analysis of BrdU
incorporationwas performed using an anti-BrdUmonoclonal antibody
(Amersham) followed by an anti-mouse/Cy3 conjugate (1:200;
Molecular Probes). The frequency of S-phase cells was calculated as a
ratio of BrdU-positive nuclei to the total Hoechst-stained nuclei.
TUNEL
Apoptosis was detected using the In Situ Cell Death Detection Kit,
POD (Roche).
Reverse transcription and real-time PCR
RNA was prepared using Trizol Reagent (Invitrogen, USA) from
cultured cells, or dissected calvaria consisting of the frontal, parietal
and interparietal bones cleared of extraneous membranes and snap-
frozen in liquid nitrogen. RNA was puriﬁed with the RNeasy MinElute
Cleanup Kit (Qiagen, USA). cDNA was prepared with the SuperScript
First-Strand kit (Invitrogen). Real-time PCR of cDNA was performed
with the LightCycler FastStart DNAmaster SYBR green 1 kit (Roche) on
a Light Cycler system (Roche). Relative expression levels were
calculated using the level of β-actin in each sample as a reference.
PCR oligonucleotide sequences are available upon request.
Statistics
Results for cell proliferation and mRNA expression levels are
presented as the mean±standard error of the mean (SEM), and were
275G. Holmes et al. / Developmental Biology 328 (2009) 273–284analyzed using the unpaired, two-tailed Student's t test. Differences
with a P value≤0.05 were considered signiﬁcant.Tissue culture
Primary calvarial osteoblasts were prepared, maintained, and
immortalized as described previously (Mansukhani et al., 2000), but
with the substitution of Dulbecco's modiﬁcation of Eagle's medium
(DMEM; Gibco BRL) forαMEM. Brieﬂy, individual calvaria of newborn
(P1) mice, consisting of the frontal, parietal, and interparietal bones,
were aseptically dissected, stripped of associated membranes, and
serially digested 5 times for 15 min each in a solution of collagenase/
dispase to liberate osteoblasts. The ﬁrst fractionwas discarded and the
remaining four were combined, washed, and plated for culture. For
differentiation assays osteoblasts were plated at 105 cells/well in aFig. 1. Coronal synostosis in the Fgfr2S252W/+ calvaria. (A) Newborn (P1) Fgfr2S252W/+ (AP) p
line, approximate position of coronal suture. (B) Alizarin red/alcian blue staining of newborn
coronal suture. The long and short arrows extending from the horizontal bar indicate the ma
whole calvaria for Alp activity in osteogenic domains of the frontal (F) and parietal (P) anlagen
for Alp activity in transverse sections of the coronal suture of WT and AP calvaria between E1
mid/upper Fgfr2S252W/+ coronal suture a relatively normal suture morphology is initially est
lower side of each panel. Vertical arrowheads at E13.5, frontal and parietal edges. Scale bars,12-well plate; after 24 h the medium was supplemented with
50 μg/ml L-ascorbic acid and 4 mM Glycerol-2-phosphate, changed
every three days. Alp activity was detected using a kit according to the
manufacturer's instructions (85L-2; Sigma-Aldrich).Protein preparation and Western blotting
Cultured cells were lysed in RIPA buffer (10 mM, Tris–HCl, pH 7.2,
150 mM NaCl, 5 mM EDTA, 0.1% SDS, 1% Na deoxycholate, 1% NP-40)
containing protease inhibitor cocktail (Complete Mini EDTA-free,
Roche) and phosphatase inhibitors (sodiumorthovanadate). For tissue
protein, calvaria were isolated from newborn pups as described
previously, snap frozen in liquid nitrogen, then homogenized in RIPA
buffer using a Polytron tissue homogenizer (Kinematika, Switzerland).
Protein concentration was determined with Bradford Protein Assayups have domed heads and short faces compared to wild-type (WT) littermates. Dotted
skulls shows synostosis of the basal (asterisk) and mid/upper (arrowhead) Fgfr2S252W/+
jor and minor directions of fusion from the starting point, discussed later. (C) Staining of
shows no clear differences betweenWTand AP littermates at E12.5 (E, eye). (D) Staining
3.5 and P1. The osteogenic fronts rapidly coalesce in the basal Fgfr2S252W/+ suture. In the
ablished by E15.5, but is slowly eliminated as OFs fuse. The endocranial surface is at the
100 μm, apply to boxed areas.
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PAGE gel. Proteinswere electrotransferred to nitrocellulosemembrane
(Protran BS85, Whatman) and incubated with the speciﬁc antibodies.
Proteins were visualized by ECL (Amersham). The antibodies used
were against Fgfr2 (SC-122; Santa Cruz); phospho-β-catenin (#9561),
phospho-Akt (#9217), total Akt (#9272), phospho-p38 (#9211) (Cell
Signaling Technology); activated β-catenin (ABC, #05-655, Upstate
Biotechnology); β-catenin (#610153, BD Transduction); α-tubulin
(T6074, Sigma-Aldrich); and actin (ab11003, Abcam).Results
The Apert mouse model was formed by a knock-in strategy, which
created a mutated Fgfr2NeoS252W allele whose expression was
suppressed by the presence of a Neo cassette (Chen et al., 2003).
Full expression of this allele was restored by crossing Fgfr2NeoS252W/+
heterozygotes with EIIa promoter-Cre transgenic mice to remove
the Neo cassette and generate Fgfr2S252W/+ offspring. Crosses of
Fgfr2NeoS252W/+ males with EIIa-Cre females gave obviously affected
pups at birth, identiﬁable by a domed head and short face (Fig. 1A).
Genotyping of tail DNA showed that affected offspring were invariably
Neo negative, and these genotypes were used for subsequent analy-
sis. Some litters were allowed to develop beyond birth; however,
Fgfr2S252W/+ animals always died within a few days, as opposed to the
variable longevity related to strength of phenotype previously
reported (Chen et al., 2003), but similar to the recent report of a
second Apert syndrome mouse model (Wang et al., 2005). Further-
more, affected pups could often be identiﬁed morphologically as early
as E13.5 and onwards, the back of the head being less rounded than in
WT littermates (not shown). Mice were also out-bred with a Swiss
Webster background, with no difference in phenotype noticed, and
are included in the analyses. Occasionally, mosaic but viable animals
having a domed head, short face andmalocclusionwere obtained, and
were also used for breeding when fertile.Fig. 2. Osteoblast gene expression in the Fgfr2S252W/+ coronal suture (RNA ISH). (A) At E13
suture, but in the basal Fgfr2S252W/+ suture Fgfr2 expression starts to become continuous bet
are more widely expressed compared to the WT in fusing Fgfr2S252W/+ sutures. (C) Noggin
expression are seen in fusing sutures. Transverse sections are adjacent (A, D) or near-adjaceCoronal suture fusion is an early embryonic event
Inspection of newborn Fgfr2S252W/+ skulls revealed extensive
coronal suture fusion (Fig. 1B). The development of the coronal suture
was therefore examined between E12.5 and P1, the period of
embryonic skull formation. Alkaline phosphatase (Alp) activity,
upregulated in pre-osteoblasts and osteoblasts (Candeliere et al.,
2001), was visualized histochemically in intact embryos (E12.5, Fig.
1C) or transverse sections covering the entire calvaria (Fig. 1D). This
showed the positions of osteogenic fronts (OFs) and areas of osteoid
and bone (unmineralized and mineralized extracellular matrix,
respectively). At E12.5 Alp staining showed slight individual variation
between littermates but no clear differences between WT and
Fgfr2S252W/+ pups (Fig. 1C). In Fig. 1D we present the progress of
coronal suture fusion at both the basal (ciliary region) and mid/upper
levels of the suture. In the WT basal coronal suture the OFs lack
osteoid until E15.5, when they also become more compact and
tapered in shape. Unlike most of the coronal suture, the OFs do not
overlap, but from E15.5 part of the parietal OF lies near forked ends of
the frontal bone for a short distance. In Fgfr2S252W/+ animals at E13.5
the gap between frontal and parietal OFs is already smaller, and by
E14.5 is bridged by a uniform band of high Alp activity, at a point near
to but above the lower limits of the frontal and parietal bones. At E15.5
the frontal and parietal osteoid is in close contact or continuous in at
least one of the two coronal sutures, and is continuous in both sutures
by E16.5 (Fig. 1D; n=6/6 pairs). The forked structure of the frontal
bone in this region was not formed in the Fgfr2S252W/+ suture.
In the mid-sutural region and higher, the WT OFs are closely
opposed by E14.5, and develop the typical overlapped arrangement by
E16.5, when they are also tapered and contain osteoid. In contrast, the
Fgfr2S252W/+ OFs were more closely opposed at E13.5 and showed a
precocious deposition of osteoid by E15.5. They were generally more
robust in appearance but still formed the overlapping arrangement by
E16.5 along the remaining length of the suture, as in the WT. The
extent of fusion seen in this region from E16.5 to P1 varied between.5, the frontal and parietal domains of Fgfr2 and Fgfr1 expression are distinct in the WT
ween the frontal and parietal domains, while Fgfr1 domains are closer. (B) Spp1 and Ocn
is not down-regulated in fusing Fgfr2S252W/+ sutures. (D) Only mild changes in Twist1
nt (B, C), with the endocranial surface to the right. Black bars, 100 μm; white bar, 50 μm.
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fusion is between overlapping OFs containing osteoid (E16.5, P1,
Fig. 1D; also Fig. 6). Also, the continued patency of much of the
Fgfr2S252W/+ coronal suture during this period, despite the closer
approximation of the OFs, indicates a much slower rate of fusion com-
pared to the basal suture. Although fusion starts in the Fgfr2S252W/+
basal suture and proceeds largely apically, in the apex of the suture
points of fusion could occasionally be found above patent areas at P1
(not shown). A small amount of fusion also occurs downwards below
the initial fusion point, towards the lower limit of the coronal suture.
These observations show that in Fgfr2S252W/+ mice coronal suture
fusion begins early in cranial development, with the coalescence of
the frontal and parietal osteogenic mesenchymal domains near the
base of the suture, and subsequent loss of the intervening sutural
mesenchyme. The early rapid progress of the Fgfr2S252W/+ OFs, and
the precocious deposition of osteoid, further suggests that the early
stages of osteoblast induction and maturation are accelerated.
Ectopic expression of genes related to osteoblast development
To determine the basis of premature suture fusionwe used RNA ISH
to examine the expression of genes characteristic of the OFs (Fgfr1, -2),
osteoblast maturation (Osteopontin, Spp1; Osteocalcin, Ocn), andFig. 3. Obliteration of the basal coronal suture. ISH for Fgfr2 (left column) and Fgfr1 (right co
the spatial progress of the OFs during fusion in a single coronal suture is shown in serial secti
theWT sections in (A) towards the base of the suture in the lowest panel (direction of vertica
direction. P, parietal; F, frontal. The endocranial surface is at the lower side of each panel. Binvolved in suture patency (Noggin, Twist1), and assessed cell
proliferation and apoptosis. In the WT, Fgfr1 and -2 become differen-
tially expressed in osteoblasts at the OFs and along the developing bone
surfaces, with a wider domain of Fgfr2 expression encompassing the
proliferating osteoprogenitors and a nested domain of Fgfr1 expression
occurring inmore mature post-proliferative osteoblasts (Fig. 2A) (Iseki
et al., 1999). This relationship was maintained in the mutant, but their
expression also reﬂected the changes seen with Alp activity. While no
differenceswere noted at E12.5 (not shown), at E13.5 the limits of Fgfr2
and -1 expression were closer in the Fgfr2S252W/+ suture compared to
the WT, with Fgfr2 expression becoming continuous at their closest
points of approximation (Fig. 2A).
Osteopontin and osteocalcin are markers of early and late
osteoblast maturation, respectively (Candeliere et al., 2001), and
their expression begins deep within the osteogenic domains before
progressing outwards towards the OFs. The timing of Spp1 expression
was similar in WT and Fgfr2S252W/+ calvaria, beginning at E14.5 in the
frontal and parietal bones and by E15.5 in the inter-parietal bone (not
shown) (Iseki et al., 1997). A major difference in expression was seen
by E15.5 in the basal coronal suture very near or within regions of
fused osteoid, where the leading edges of Spp1 expression extended
closer to each other in the Fgfr2S252W/+ mouse (Fig. 2B). It should be
noted that the osteoid was initially deposited by osteoblastslumn) in transverse sections of E15.5 WT (A) and (B) Fgfr2S252W/+ (AP) calvaria. In (B)
ons, proceeding from a point of fusion in the highest panel (equivalent to the position of
l arrow; see small arrow in Fig. 1B). Serial sections are separated by 90 μm in the vertical
ar, 100 μm.
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frontal and parietal bones of Fgfr2S252W/+ sutures, in conjunctionwith
osteoid or mineralized bone, was seen from E15.5–E16.5 (not shown).
Like Spp1, Ocn expression was more widespread in Fgfr2S252W/+
calvaria in areas of early fusion (Fig. 2B). Spp1 and Ocn expressionwas
similar betweenWTand Fgfr2S252W/+ animals in patent regions of the
coronal suture (not shown).
The BMP inhibitor Noggin has been proposed as a regulator of
suture patency. It can be down-regulated during FGF-induced
craniosynostosis, and ectopic noggin expression can maintain suture
patency (Warren et al., 2003). Noggin was expressed in the WT OFs
and along the bone plates in a similar pattern to the Fgfrs (Fig. 2C).
Generally, no difference other than its advanced expression in
Fgfr2S252W/+ OFs compared to WT sutures was seen. However, its
expression did not decrease in advance of coronal suture fusion in the
Fgfr2S252W/+ mouse, but bridged the sutural mesenchyme separating
the bone plates prior to fusion (Fig. 2C).
Inactivating mutations of the bHLH factor H-TWIST are responsible
for Saethre–Chotzen syndrome in humans, involving coronal suture CS,
and Twist1+/−mice also suffer coronal suture CS (Carver et al., 2002;
el Ghouzzi et al., 1997; Howard et al., 1997). Twist1 was expressed in
immature skeletal mesenchyme, the OFs, and in sutural mesenchyme at
E14.5 (Fig. 2D) and E15.5 (not shown). Apart from the more uniform
expression of Twist1 across Fgfr2S252W/+ coronal suture mesenchyme
expressing Alp and Fgfr2 before fusion, we found no differences in
Twist1 expression between WT and Fgfr2S252W/+ calvaria.
In Fig. 3 the process of fusion is traced in a single Fgfr2S252W/+
coronal suture at E15.5, progressing from the initial fusion point
towards the base of the suture (Fig. 3B; see small arrow in Fig. 1B).
Fusion is preceded by the advance of Fgfr2 expression in the OFs into
the sutural mesenchyme. Once the Fgfr2-expressing OFs meet and
form a continuous sheet joining frontal and parietal mesenchyme,
Fgfr2 is down-regulated, Fgfr1 continues to be expressed, and ﬁnally
osteoid is deposited, obliterating the suture. Fgfr2-expressing osteo-
blasts are relegated to the surface of the new bone, contiguous with
Fgfr2-expressing cells in the frontal and parietal bones. Grossly
normal bone formation proceeds from this point. The WT sutural
arrangement in this area is shown in Fig. 3A.
In mice carrying activating Fgfr mutations signiﬁcant increases in
the expression of osteoblast marker genes such as Runx2, Spp1, and
Ocn prior to the time of fusion have been reported (Eswarakumar
et al., 2004; Zhou et al., 2000). We compared the mRNA expression
levels in WT and Fgfr2S252W/+ calvaria of various genes relevant to the
osteoblast phenotype and suture patency using quantitative real-time
RTPCR. The stages examined were E15.5 (Fig. 4), when fusion is
beginning but much of the coronal suture is open, and E17.5 (not
shown), when coronal suture fusion is well advanced. No signiﬁcant
differences were seen in expression levels between WT and
Fgfr2S252W/+ calvaria of genes involved in OF function (Fgfr1 and -2
IIIc mesenchymal isoforms) or general osteoblast activity andFig. 4. Osteoblast gene expression in E15.5 calvaria. Quantitative real-time RTPCR of RNA
increases in later differentiation markers in Fgfr2S252W/+ mice compared to WT levels. Exp
samples, relative to a singleWTsample for each gene. Differences in expression levels betweendifferentiation (Alp, Runx2, Col1a1), or maturation (Spp1, Ocn, Mepe,
Sost), although the expression of these latter genes was mildly
elevated in Fgfr2S252W/+ compared to WT calvaria at E15.5. These
differences were smaller at E17.5, although loss of much of the suture
at E17.5 would not of itself be expected to result in a large change in
these expression levels as these genes are expressed in osteoblasts
beyond the sutural zone. The results show that the Apert Fgfr2
mutation does not cause signiﬁcantly higher steady-state expression
levels of these genes in osteoblasts. The levels of Noggin, Gdf6, or
Twist1, the loss of any of which is associated with synostosis, were
not altered during the fusion process (as seen previously for Noggin
and Twist1; Figs. 2C, D).
The expression patterns of genes in the developing calvarial bones
conﬁrm our initial ﬁnding of accelerated osteoblast induction and
failure of the basal OFs to arrest their progress at the sutural
mesenchyme. These changes occur without enhanced levels of
osteoblast gene expression. Once a contiguous osteogenic domain is
established in place of the sutural mesenchyme, a relatively normal
sequence of bone formation occurs. Ectopic osteoid is deposited both
between the frontal and parietal domains during their fusion, and in
the higher unfused OFs of the Fgfr2S252W/+ coronal suture.
Altered proliferation is not sufﬁcient to account for suture fusion
The domain of Fgfr2 expression in calvaria coincides with
osteoblast proliferation (Iseki et al., 1999), and activated Fgfr2
signaling has been reported to increase cell proliferation in vivo
(Eswarakumar et al., 2004). Cell proliferation in the coronal sutures of
the WT and Fgfr2S252W/+ mouse was assessed using pre-natal BrdU
incorporation (Fig. 5) and by detecting Ki67 (not shown), with similar
results. As the frontal and parietal bones are derived from neural crest
and mesoderm, respectively (Jiang et al., 2002), proliferating cells
were counted separately in each OF in case cell lineage-speciﬁc
differences were present. In fusing Fgfr2S252W/+ sutures, counts were
performed in OFs above the level of fusion and compared to equivalent
areas in WT sutures.
At E12.5 the frontal and parietal osteogenic fronts are widely
separated both in WT and Fgfr2S252W/+ animals (Fig. 1C). BrdU
incorporation was consistently higher in Fgfr2S252W/+ frontal and
parietal regions compared to WT, though these differences were not
always statistically signiﬁcant (Fig. 5A). No increase in the proportion
of BrdU-positive cells was seen in Fgfr2S252W/+ frontal or parietal OFs
compared to WT between E13.5 and E14.5 (Fig. 5A), nor in the
intervening sutural mesenchyme at E13.5 (not shown). At E15.5,
comparing a WT suture to an Fgfr2S252W/+ suture beginning to fuse,
only a mildly greater proportion of BrdU-positive cells was seen in the
WT frontal OF. At E16.5 a signiﬁcant drop in BrdU-positive cells was
seen in Fgfr2S252W/+ sections above the region of fusion compared to
WT (Fig. 5A). This difference at E16.5 was similar in six pairs
compared (three each on the original and out-bred backgrounds). Thisfrom WT (black; WT) and Fgfr2S252W/+ (white; AP) whole calvaria shows only minor
ression levels are shown as the mean±SEM of three or six WT and three Fgfr2S252W/+
WTand Fgfr2S252W/+ sampleswerenot signiﬁcantwhen analyzedby the Student's t test.
Fig. 5. Proliferation in coronal sutures during embryonic calvarial development. (A) The number of BrdU-positive nuclei is shown as a percentage of total nuclei within deﬁned regions
of the individual OFs (frontal and parietal) or total (frontal plus parietal) sutures between E12.5 and E16.5.WT, black; AP (Fgfr2S252W/+),white. Values are shownas themean±SEMof
4–7 alternate sections of a single suture. Asterisks indicate statistically signiﬁcant differences determined using the Student's t test (Frontal: E12.5, P=0.039; E15.5, P=0.040; E16.5,
P=0.003; Parietal: E16.5, P=0.004; Total: E16.5, P=0.0004). (B) At E16.5, proliferation (BrdU incorporation, green nuclei) within OFs (Alp-expressing domains, red) is decreased in
upper Fgfr2S252W/+ sutures in advance of suture fusion. Bar, 70 μm.
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frontal and parietal OFs facing each other prior to fusion (Fig. 5B). No
consistent differences in proliferation were seen between neural
crest- and mesoderm-derived osteoblasts.
Thus, despite an initial increase, OF proliferation is not enhanced
during basal sutural fusion, and abruptly decreases compared to the
WT during later sutural fusion, perhaps reﬂecting accelerated
maturation at the expense of proliferation occurring in the apical
OFs in the Fgfr2S252W/+ mice.
Apoptosis is secondary to suture fusion
In the initial report of this Apertmousemodel, apoptosiswas seen to
be signiﬁcantly higher in the post-natal Fgfr2S252W/+ coronal sutureFig. 6. Apoptosis during coronal suture fusion. TUNEL-positive cells were only seen in later F
wild type; AP, Fgfr2S252W/+; ALP, alkaline phosphatase. Bar, 100 μm.compared to the WT, and it was proposed that this allowed sutural
fusion (Chen et al., 2003). Apoptosis in the embryonic coronal suture is
negligible before E17.5 (Bourez et al.,1997;Rice et al.,1999).Weassessed
apoptosis in the developing coronal suture by TUNEL. Before E16.5, few
or no apoptotic cells were detected in eitherWTor Fgfr2S252W/+ coronal
sutures, despite their cleardifferences in sutural development, including
those sutures at E15.5 where Alp activity between the frontal and
parietal boneswas continuous prior to or during osteoid deposition (not
shown). At E16.5 apoptotic cells appeared in the Fgfr2S252W/+ coronal
sutures, but were strictly limited to sites of osteoid contact between the
frontal and parietal bones and not seen in the more extended area of
decreased proliferation above this point in the Fgfr2S252W/+ coronal
suture (Fig. 6). Apoptosis therefore appeared to be a consequence rather
than a cause of sutural fusion in Fgfr2S252W/+ mice.gfr2S252W/+ coronal sutures (E16.5) in areas of frontal and parietal osteoid contact. WT,
280 G. Holmes et al. / Developmental Biology 328 (2009) 273–284Cartilage abnormalities in the Fgfr2S252W/+ calvaria
Ectopic cartilage in the cranial vault was seen in the second Apert
mouse model (Wang et al., 2005). We noted apical overgrowth of the
orbito-sphenoid cartilage, and an ectopic pair of short cartilage bands in
the sagittal suture in Fgfr2S252W/+ mice at E16.5 (Supplemental Fig. 1).
In contrast to the rapid suture closure we see in the Fgfr2S252W/+
mouse, ectopic cranial cartilage canhinder suture formation (Holmbeck,
2005). In the Fgfr2S252W/+ mouse any link between ectopic cartilage
and coronal suture fusion is unknown, although fusion occurred in
areas where the difference between WT and Fgfr2S252W/+ cartilage
was minimal (the early basal suture) or where cartilage did not occur
(the upper suture).
Behavior of osteoblasts from Fgfr2S252W/+ mice in culture
The experiments described in the preceding sections highlight a
complex developmental scenario, in which the Fgfr2S252W/+ mice
showed a very early suture closure phenotype. Osteoblasts diffe-
rentiated at an accelerated rate and did not respond to physiological
signals that inhibit osteoblast induction in the suture. A slight increase
in the number of proliferating osteoblasts in OFs was observed at early
stages of embryonic development (E12.5). To better understand the
dynamics of osteoblast proliferation and differentiation determining
Fgfr2-induced craniosynostosis, we examined the behavior of osteo-
blasts isolated from the calvarial of Fgfr2S252W/+ mice and WT
littermates in culture. Primary calvarial osteoblasts were isolated from
pure P1 Fgfr2S252W/+ and from WT littermate mice. The genotype of
the cultured cells was veriﬁed by PCR (data not shown). In some cases,
these cells were immortalized by infection with a retroviral vector
expressing the polyoma large T-Ag (LT).
Fgfr2S252W/+ cells proliferate faster in culture
BrdU incorporation studies demonstrated that primary osteoblast
cultures isolated from Fgfr2S252W/+ mice divide at a signiﬁcantly
higher rate than cells isolated from WT littermates (Fig. 7A).
P1 calvarial osteoblasts from a different pair of Fgfr2S252W/+ and WTFig. 7. Proliferation of WT and Fgfr2S252W/+ osteoblasts in culture. (A, B) BrdU incorporation
Cells were grown in either 10% (A) or 0.4% (B) serum, then treated with FGF1 for 24 h, with
(black squares) osteoblasts. Cells were grown in 10% FCS.littermate mice were also examined after LT immortalization. BrdU
incorporation showed that the Fgfr2S252W/+ cells have a higher rate of
DNA synthesis than the WT. Addition of 5 or 20 ng/ml recombinant
FGF1 to the culture medium increased proliferation of all cells but did
not alter the ratio of BrdU incorporation betweenWTand Fgfr2S252W/+
cells (Figs. 7A, B). A growth curve (Fig. 7C) also showed a signiﬁcantly
faster rate of growth of Fgfr2S252W/+ relative to the WT cells.
Accelerated differentiation of Fgfr2S252W/+ cells in culture
Calvarial osteoblasts isolated from a P1 Fgfr2S252W/+ and a WT
littermate were cultured in differentiation medium and stained at
regular intervals for Alp. Fig. 8A demonstrates that the Fgfr2S252W/+
osteoblasts stained positive for Alp earlier and more strongly than the
WT littermate osteoblasts. We and others previously showed that Akt
activation promotes osteoblast differentiation (Kawamura et al., 2007;
Raucci et al., 2008). By Western blot we showed that phospho-Akt is
upregulated in Fgfr2S252W/+ osteoblasts in comparison to WT
osteoblasts (Fig. 8B), consistent with an increased ability to
differentiate. As also noted previously, osteoblasts expressing
increased levels of phospho-Akt have increased amounts of activated
β-catenin, a central molecule in Wnt signaling, which promotes
osteoblast differentiation (Raucci et al., 2008). In line with the
observation that Fgfr2S252W/+ cells differentiate faster, they had
decreased levels of phospho-β-catenin and high levels of active β-
catenin. (Fig. 8B). Increased phospho-Akt was also detected in
calvarial tissues of two Fgfr2S252W/+ animals, along with increased
phospho-p38 (Fig. 8B), another positive regulator of osteoblast
differentiation (Hu et al., 2003).
To conﬁrm the increased rate of differentiation of Fgfr2S252W/+
osteoblasts, we used LT immortalized calvarial osteoblasts isolated
from newborn Fgfr2NeoS252W/+ mice, which contain the Neo cassette
upstream of the Apert S252W mutation. These mice carry the Apert
mutation but the presence of the Neo cassette compromises its
expression. These cells were divided into two populations and
infected with the pLXS-Cre-EGFP virus (designed to excise the Neo
cassette) or with the pLXS-EGFP virus only. Fig. 8C shows successful
excision of the Neo cassette from a majority of the cells after infectioninto primary (A) and immortalized (B) Fgfr2S252W/+ (white, grey) and WT (black) cells.
BrdU added for the last 4 h. (C) Growth curve of Fgfr2S252W/+ (open diamonds) and WT
Fig. 8. Differentiation of Fgfr2S252W/+ and WT osteoblasts in culture. (A) Time course of Alp activity of immortalized Fgfr2S252W/+ (AP) and WT cells in differentiation medium. (B)
Western blots showing greater activation of signaling proteins involved in differentiation in immortalized Fgfr2S252W/+ (AP) compared to WT osteoblasts (upper panel) and in
newborn calvaria (lower panel). (C) Induction of Fgfr2s252w expression by Cre virus infection of immortalized Fgfr2NeoS252W/+ osteoblasts, compared to control infection, shown by
gDNA PCR (left) and quantitative real-time RTPCR (right). (D) The control- and Cre-infected cells in (C) were incubated in differentiation medium, and the relative expression levels
of various osteoblast differentiation markers were determined by quantitative real-time RTPCR on the days indicated.
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expression of Fgfr2 mRNA. After 14 days in differentiation medium
cells infected with the Cre virus stained strongly for Alp, indicating
that they differentiate faster than control cells, while WT osteoblasts
did not show any difference in Alp expression between Cre-infected
and uninfected cells (data not shown).Wemeasured the expression of
several osteoblast differentiation markers at various times after
infection with the Cre or the control virus. Cre-infected cells
expressing activated Fgfr2 showed a strong increase in the expression
of Col1a1, Runx2, Alp, and Timp3 mRNAs relative to the controls
(Fig. 8D). Thus, the expression of activated Fgfr2 results in faster
osteoblastic differentiation.
It has been widely observed that prolonged treatment of
osteoblasts in culture with exogenous FGF prevents differentiation
(Mansukhani et al., 2000; Tang et al., 1996). We therefore examined
the response of Fgfr2S252W/+ and WT osteoblasts to exogenous FGF1.
Fgfr2S252W/+ and WT cells continuously incubated with 10 μg/ml of
FGF1 did not differentiate even after 14 days in differentiation
medium. A dose–response experiment showed that no concentration
of exogenous FGF1 could accelerate differentiation, with the response
varying from no effect to complete inhibition of differentiation. Thus
Fgfr2S252W/+ cells respond to exogenous FGF as their WT counterpart
(data not shown).
Expression of Fgfr2 and Fgfr1 in Fgfr2S252W/+ and WT cells
It has been proposed that downregulation of Fgfr2 expression
during in vivo osteoblast development allows signaling from Fgfr1 and
osteogenic differentiation (Morriss-Kay and Wilkie, 2005). It has also
been reported that humanApert osteoblasts express low levels of Fgfr2
protein in culture (Lemonnier et al., 2000). We therefore determinedthe levels of expression of Fgfr1 and Fgfr2 in several matched cultures
of WT and Fgfr2S252W/+ osteoblasts derived from newborn litters.
While the expression levels of Fgfr1 were similar in all samples, we
found a variable reduction in the expression of Fgfr2, both at the RNA
and protein level, in Fgfr2S252W/+ compared toWTosteoblasts, varying
from about 20% of the matched WT osteoblasts, to levels only slightly
lower (70–80%) (Supplemental Fig. 2A). It has been shown that FGF
signaling downregulates the expression of Fgfr2, but not of Fgfr1, in
several cell types (Ali et al., 1995), and we therefore determined
whether this was also the case in osteoblasts. FGF treatment of both
WT and Fgfr2S252W/+ osteoblasts strongly reduced the expression of
both Fgfr2 RNA and protein, while expression of Fgfr1 was not
signiﬁcantly affected (Supplemental Fig. 2B). We therefore consider it
likely that the variable downregulation of Fgfr2 expression observed in
Fgfr2S252W/+ osteoblasts could be due to a degree of autocrine FGF
signaling taking place in these cells. Since themajor activating effect of
the Apert S252W mutation is to increase and broaden FGFR2 afﬁnity
for FGF ligands (Yu et al., 2000), endogenous production of low
amounts of Fgf could downregulate Fgfr2 expression. Because of the
downregulation of Fgfr2 expression, all Fgfr2S252W/+ cells had
relatively higher levels of Fgfr1 versus Fgfr2 than WT cells.
Discussion
How the cranial sutures are initially established and the integrity of
the sutural mesenchyme between bone fronts subsequently main-
tained is not clearly understood. FGF, TGFβs, and BMPs, expressed in
both the osteogenic mesenchyme and underlying dura mater, all
regulate suture patency (Opperman, 2000). Expression studies and
the application of FGF to cultured crania has shown a correlation
between low FGF levels, Fgfr2 expression, and osteoblast proliferation
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osteoblast differentiation on the other (Iseki et al., 1997; Iseki et al.,
1999). At the OFs and along the bone surfaces, there is a general
progression with increasing maturation from proliferating osteopro-
genitors expressing Fgfr2 to post-proliferative osteoblasts expressing
Fgfr1, and mature osteoblasts may express neither receptor (Iseki
et al., 1999; Johnson et al., 2000). It is hypothesized that FGF signals
drive the progress of the OFs, and that suture patency is controlled, at
least in part, by the inﬂuence of an FGF gradient on the balance
between osteoblast proliferation and differentiation, with aberrant
FGF signaling triggering a switch from Fgfr2 expression and prolifera-
tion to Fgfr1 expression and differentiation, ultimately resulting in
suture fusion (Morriss-Kay and Wilkie, 2005).
Despite the variety of murine models of deleted or activated Fgfr2
available, a description of the initiation and progress of coronal suture
fusion, or a consensus on how activated Fgfr2 causes it, is lacking.
Targeted deletion of Fgfr2 in osteoblasts shows that it is not entirely
essential for proliferation in the OFs (Eswarakumar et al., 2002; Yu
et al., 2003), while the proliferative effects of activated Fgfr2 reported
in the embryonic coronal suture were either transient in a Crouzon
C342Y model (Eswarakumar et al., 2004) or undetected in the Apert
model studied in this report (Chen et al., 2003). In mice with deleted
or activated Fgfr2, differentiation was also decreased or enhanced,
respectively (Eswarakumar et al., 2004; Eswarakumar et al., 2002).
Furthermore, almost all models show post-natal coronal CS, but the
relationship of this later fusion to earlier embryonic changes is not
clear. Embryonic CS has been seen in only one mouse model, in which
ablation of the mesenchymal isoform Fgfr2-IIIc resulted in ectopic
expression of the epithelial isoform Fgfr2-IIIb in osteoblasts, but the
process of fusion was not described (Hajihosseini et al., 2001). The
previous description of the mice studied in this report (Chen et al.,
2003) noted a variable phenotype and viability of affected mice and
only post-natal fusion of the coronal suture, which is at odds with our
ﬁndings. This suggests that some of these mice were variably chimeric
due to inefﬁcient Cre activity, which may allow a much longer period
of suture patency before fusion occurs.
In our study of this Apert model, we found CS to begin very early in
cranial development. Near the base of the Fgfr2S252W/+ coronal suture,
the frontal and parietal osteogenic domains rapidly coalesce between
E13.5–E15.5, as seen in the successive convergence of the expression
domains of Fgfr2, followed by Alp, and then Fgfr1. It appears as if the two
osteogenic domains simply advance until they join each other, with no
formal separation ever being established. Osteoid is then deposited
within a continuous osteogenic layer to join the two bones, and grossly
normal bone formation follows. Perhaps surprisingly, further up the
coronal suture the OFs form the increasingly more compact wedges of
proliferating cells, post-proliferative osteoblasts, and osteoid, with the
overlap typical of the WT suture. In contrast to the rapid fusion of soft
mesenchyme in the basal suture, sutural fusion occurs from E15.5
between the tip of each remaining OF and the opposing osteoid,
progressing apically but at amuch slower rate than occurred in the basal
suture. Enhanced osteoblast maturation is also seen in the developing
Fgfr2S252W/+ coronal suture, with the precocious deposition of osteoid
across the sutural mesenchyme and in the more apical unfused OFs.
Analysis of proliferation showed a modest increase at E12.5 in the
Fgfr2S252W/+ suture. From E13.5–E14.5 in Fgfr2S252W/+ basal sutural
areas ectopic expression of Alp and Fgfr2 is accompanied by ectopic
proliferation. In the separate OFs above this, no difference is seen
compared to theWT, suggesting that the increased advance of the OFs
is not driven by increased proliferation. Further, as fusion continues in
the Fgfr2S252W/+ OFs higher in the suture at E16.5, there is a
signiﬁcant decrease in proliferation. This is likely to be the
consequence of the shift towards greater osteoblast maturation
occurring in the Fgfr2S252W/+ suture at this time.
Apoptosis has been proposed as a mechanism to both prevent and
promote suture fusion (Dry et al., 2001; Furtwangler et al., 1985; Riceet al., 1999). In the initial report of the mice used in the present study,
increased post-natal apoptosis was proposed as the possible mecha-
nism of suture fusion (Chen et al., 2003). Apoptosis also occurs during
normal post-natal mid-line suture fusion (Fong et al., 2004). As we
found it occurs as a late event in Fgfr2S252W/+ sutural fusion, it is likely
to be a consequence rather than a cause of synostosis.
The primary event of suture fusion that must be understood in the
Fgfr2S252W/+ mouse is the failure of the OFs to halt their progress
across a discreet distance of sutural mesenchyme in the basal suture.
Fgfr2 is expressed at a low level throughout thismesenchyme, rising in
level at the OFs (Johnson et al., 2000). In the normal coronal suture, a
key role in halting the progress of OFs is played by the bHLH factor,
Twist1, which is expressed in sutural mesenchyme, OFs, and immature
skeletal mesenchyme (Bialek et al., 2004; Connerney et al., 2006;
Johnson et al., 2000; Rice et al., 2000). Haploinsufﬁciency of H-TWIST
in humans is the cause of coronal suture fusion in Saethre–Chotzen
syndrome (el Ghouzzi et al., 1997; Howard et al., 1997), and in mice
with an inactivating Twist1 mutation causing CS (Carver et al., 2002)
ectopic induction of Fgfr2 is seen in sagittal and coronal sutural
mesenchyme (Connerney et al., 2008; Connerney et al., 2006; Rice
et al., 2000). The control of Fgfr2 expression by Twist1 is complex,
involving a balance between Twist1 homodimers, which activate Fgfr2
expression in the OFs, and Twist1/E-protein heterodimers, which
repress Fgfr2 expression in the sutural mesenchyme (Connerney et al.,
2008; Connerney et al., 2006); furthermore, Fgf signaling can
upregulate Twist1 expression (Rice et al., 2000). A simple scenario
in the Fgfr2S252W/+ coronal suture is that excessive Fgfr2 activation in
the suture mesenchyme overcomes the suppressive Twist-based (or
other) signal, allowing conversion to the osteoblast fate, with the
resulting loss of the suture. This possibility is supported by the ﬁnding
that in the Twist1+/−mouse, suppression of wild-type Fgfr2 activity
is enough to prevent CS (Connerney et al., 2008), which suggests that
the efﬁcacy of Twist1 function depends on the relative strength of
Fgfr2 signaling. This mechanism would not require enhanced
osteoblast proliferation or apoptosis in the Fgfr2S252W/+ mutant, or
changes in Twist1 expression, none of which were observed during
the early period of suture fusion. The heightened sensitivity of mutant
Fgfr2 to Fgfs would also explain why the OFs of the Fgfr2S252W/+
calvaria advance more rapidly compared to theWT OFs prior to suture
fusion. Another similarity between the Fgfr2S252W/+ and Twist1+/−
mice is the appearance of Alp-expressing cells within sutural
mesenchyme at E14.5 in the Twist1+/− coronal suture (Merrill et
al., 2006). These authors showed disruption of the neural crest/
mesoderm boundary between frontal and parietal domains and
mixing of the cell lineages. While the contribution of this mixing to
CS is unknown, its possible occurrence in the Fgfr2S252W/+ mouse
would be an important avenue of investigation.
Noggin has also been proposed to act as a brake on OF expansion,
its presence limiting the promotion of differentiation by BMPs. FGF
signaling can down-regulate noggin expression, allowing differentia-
tion of the suture mesenchyme across a post-natal suture (Warren
et al., 2003). However, we did not see down-regulation of Noggin at
the OFs prior to suture fusion, and its role in embryonic sutural deve-
lopment is still unknown.
While calvarial osteogenic mesenchyme is generally thought to
arise fromwithin the dermal membrane by induction and recruitment
of cells to the osteoblast fate, recent evidence suggests that it arises
within a separate skeletogenic mesenchyme established by the
proliferation and migration of independent cell populations from
the baso-lateral regions of the calvaria (Yoshida et al., 2008). While
cell migrationwas apparent at E13.5, it is not yet clear whether the OFs
represent the frontier of these migrating and proliferating cells, or
mark a secondary wave of osteoblast induction and growth once the
skeletogenic mesenchyme is in place. In the former case, activated
Fgfr2 must act in the Fgfr2-expressing osteoprogenitors to overcome a
signal that prevents their expansion into the sutural mesenchyme. The
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osteoblasts at E12.5 and their closer approximation by E13.5 may
therefore represent an early enhancement of osteoblast expansion by
Fgfr2 signaling in the Fgfr2S252W/+ calvaria.
The failure of basal suture formation is in contrast to the ability of
Fgfr2S252W/+ osteoblasts in the higher suture to respond to develop-
mental cues and initially form the appropriate sutural architecture,
which persists to varying degrees, despite the similar closer
approximation of the OFs. This suggests that the processes of suture
formation and fusion differ signiﬁcantly between the basal and higher
suture, or may reﬂect a change in the interactions of suture
mesenchyme and osteoblasts as the OFs change from a rapidly
expanding soft mesenchyme to a compact mineralizing osteoid.
However, the Fgfr2S252W/+ osteoblasts in the upper suture do behave
abnormally. Prior to fusion proliferation markedly decreases in the
remaining suture at E16.5 compared to the WT, while maturation, as
suggested by the increased deposition of osteoid, is enhanced,
suggesting a shift in the balance between proliferation and diffe-
rentiation in the OFs. Given that the expression domains of Fgfr2 and
Spp1 are mutually exclusive (Iseki et al., 1997), and that osteoid is
initially deposited by osteoblasts expressing Fgfr1 but not Spp1, it is
likely that the activated Fgfr2 signaling speciﬁcally enhances early
osteoblast maturation, perhaps by speeding the progression to Fgfr1
expression.
Coronal suture development in the Fgfr2S252W/+ mouse bears
striking similarities to the human Apert suture pathology. The early
fetal occurrence of Apert sutural fusion (Kreiborg and Cohen,1990) and
the progressive nature of coronal suture fusion from an inferior
location (Albright and Byrd, 1981) have been noted. In particular, the
late fetal Fgfr2S252W/+ murine coronal suture is very similar to that of
the fetal Apert skull shown by Mathijssen et al. (1996), where sutural
agenesis and osseous obliteration occur in the basal portion of the
coronal suture but a recognizable suture is formed both in the upper
suture and at its very base. These similarities between the Fgfr2S252W/+
mouse and human Apert syndrome suggest that this Apert mouse
model is a promising model for developing preventative therapies
against CS, and it has already been used to assess the effectiveness of
MEK inhibitors, which reduce ERK activation and therefore FGF
signaling (Shukla et al., 2007). While it might be thought that the
early synostosis alone could constrain later sutural growth and ensure
continued fusion, this study showed that synostosis is an ongoing
process and that mature sutures can still fuse even if the early synos-
tosis is minimized or prevented by treatment with FGF signaling
inhibitors in utero (Shukla et al., 2007). The enhanced osteoblast
activity in the OFs of the mature mutant coronal sutures seen in our
study is in line with this ﬁnding.
To better understand the intrinsic alterations in osteoblasts caused
by the expression of activated Fgfr2, we cultured primary osteoblasts
from the calvaria of WT and Fgfr2S252W/+ mice. We found that
Fgfr2S252W/+ cells clearly proliferate faster than the WT, and showed
an increased ability to differentiate, in agreement with ﬁndings from
similar osteoblasts derived from the second Apert mousemodel (Yang
et al., 2008). The increased proliferation of Fgfr2S252W/+ cells in
culture supports the notion that the slight increase in BrdU
incorporation observed in vivo at E12.5 could contribute to the
accelerated suture closure in Fgfr2S252W/+ mice. Similarly, the
increased ability to differentiate, that has also been observed in
other laboratories in both human Apert (Lomri et al., 1998) andmouse
Fgfr2S252W/+ osteoblasts (Yang et al., 2008), is consistent with the
accelerated maturation of osteoblasts in the basal and higher coronal
suture.
How aberrant FGF signaling from the Apert Fgfr2 would promote
both proliferation and differentiation, seemingly antithetic processes,
is still unclear. Since it has been proposed that in osteoblasts, Fgfr2
signaling is linked to proliferation and Fgfr1 to differentiation, we
explored whether the levels of expression of these receptorscorrelated with the increased ability of Fgfr2S252W/+ cells to diffe-
rentiate. While the levels of Fgfr1 expression appeared rather uniform,
we found a variable reduction of Fgfr2 expression in Fgfr2S252W/+ cells
in comparison toWTcontrols. This is likely due to the downregulation
of Fgfr2 expression by some degree of autocrine FGF signaling in these
cells, a notion supported by the ﬁnding that treatment of Fgfr2S252W/+
osteoblasts with the Fgfr inhibitor SU5402 increased expression of
Fgfr2 (G. R. and C. B. unpublished results). The accelerated
differentiation of Fgfr2S252W/+ cells in culture is in contrast to the
behavior of osteoblasts transfected to express high and unregulated
levels of activated Fgfr2, which are strongly inhibited in differentiation
(Mansukhani et al., 2000), and tends to support the hypothesis that
high levels of Fgfr2 signaling promote osteoblast proliferation and
inhibit differentiation. In culture, Fgfr1 is expressed at higher levels
than Fgfr2 in all osteoblast WT cultures we examined. Since Fgfr2
expression is also reduced further in Fgfr2S252W/+ cells, this could
argue in favor of the hypothesis that the relative increase in Fgfr1
expression could play a role in accelerating osteoblast maturation in
Fgfr2S252W/+ versus WT cells.
In conclusion, our studies highlight a complex process of FGF-
induced craniosynostosis that occurs very early in embryonic cranial
development. Sutural mesenchyme cells and/or osteoprogenitor cells
in the OFs expressing activated Fgfr2 do not respond to signals that
prevent osteoblast induction in the presumptive suture. Osteopro-
genitor cells expressing the Apert mutation have an intrinsic ability to
proliferate faster than the WT, a property easily detected in culture,
but which is only observed at very early developmental times in vivo,
probably because of the presence of other contrasting signals. These
cells also differentiate faster both in vitro and in vivo, so that we
observe a premature and uncontrolled appearance of mature
osteoblasts where normally the presence of undifferentiated
mesenchyme marks the suture. Presently, the prevailing notion of
how cranial OFs advance and the skull bones are formed is that
undifferentiated cells in the suture mesenchyme are recruited or
induced to assume the osteoblastic fate. It has however been recently
proposed that osteoprogenitor cells, derived from bone primordia in
the base of the skull, advance and migrate into the suture
mesenchyme until an appropriate stimulus halt their progression. In
either case our results strongly support the notion that the critical
event in FGFR2-induced craniosynostosis is the failure to respond to
stimuli that would halt the recruitment or the advancement of
osteoprogenitor cells at the sites where sutures should normally form.
Once past this “point of no return,” a relatively normal progression of
osteoblast differentiation and bone formation occurs.
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